Zilovertamab vedotin

Antibody–drug conjugate

Also known as MK-2140, VLS-101

Phase 2/3underway

Evidence outlook · registrational

Diffuse Large B-Cell Lymphoma: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2027-09-24.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Phase 2/3 (2)
Diffuse Large B-Cell Lymphoma
NCT07917754 · Merck Sharp & Dohme LLC
2026-12-13 – 2037-03-13 · Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
What this study did
NCT05139017 · Merck Sharp & Dohme LLC
2022-01-14 – 2027-09-24 · DLBCL, Diffuse Large B-Cell Lymphoma
What this study did
Phase 2 (6)
Diffuse Large B-Cell Lymphoma
NCT05144841 · Merck Sharp & Dohme LLC
2022-01-08 – 2026-04-21 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma
What this study did
Other / comorbidity
NCT07913594 · Olivia Newton-John Cancer Research Institute
2027-01-01 – 2030-12-31 · Peripheral T-Cell Lymphoma Refractory
What this study did
NCT05458297 · Merck Sharp & Dohme LLC
2022-07-21 – 2029-05-17 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
What this study did
NCT04504916 · VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2020-10-07 – 2023-06-12 · Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
What this study did
Phase 1/2 (2)
Diffuse Large B-Cell Lymphoma
NCT06395103 · Merck Sharp & Dohme LLC
2024-08-16 – 2029-03-31 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
What this study did
Other / comorbidity
NCT05562830 · Merck Sharp & Dohme LLC
2022-11-16 – 2029-02-26 · Urothelial Carcinoma
What this study did
Phase 1 (1)
Diffuse Large B-Cell Lymphoma
NCT03833180 · VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2019-03-14 – 2023-12-18 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, Richter Transformation Lymphoma, Burkitt Lymphoma, Lymphoplasmacytoid Lymphoma, T-cell Non-Hodgkin Lymphoma, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Diffuse Large B-Cell Lymphoma: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zilovertamab Vedotin: this drugPhase 2/3Antibody–drug conjugateROR1not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
AcalabrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Purinostat MesylatePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
SHR-A1912Phase 3Antibody–drug conjugateCD79bnot yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
IM-1021
Phase 1(overall)
Antibody–drug conjugateROR1
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zilovertamab vedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
Phase 2/3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-09-24 · NCT05139017 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-12-13 · NCT06890884 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 2Peripheral T-Cell Lymphoma RefractoryNot yet recruiting
Est. primary completion 2028-12-31 · NCT07913594 · CT.gov ↗
What to watch
2029 (5)
February 2029 (1)
Phase 1/2Urothelial CarcinomaActive not recruiting
Est. primary completion 2029-02-26 · NCT05562830 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-03-31 · NCT06395103 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2029-04-26 · NCT05406401 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation LymphomaActive not recruiting
Est. primary completion 2029-05-17 · NCT05458297 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-07-02 · NCT06717347 · CT.gov ↗
What to watch
2037 (1)
March 2037 (1)
Phase 2/3Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2037-03-13 · NCT07917754 · CT.gov ↗
What to watch

See the full readout calendar ↗